Healthier Markets. Healthier Lives.

Innovative finance for affordable and accessible healthcare

We are a social finance company with a difference. We are motivated by purpose, not profit.

Using innovative finance tools, we secure lower prices and sustainable supply of medical products for people in low- and middle-income countries. Our work combines commercial insight and rigour with a relentless pursuit of health impact.

MedAccess is an independent company, wholly owned by the UK’s CDC Group plc.

OUR IMPACT

Read our 2020 Annual Report

COVID-19 brought the extent and consequences of unequal access to healthcare into sharp focus. Find out how our partnerships are increasing access to life-saving healthcare products.

Find out more

Two scientists using a Hologic Panther machine

ABOUT US

Who we are

We believe in a world where everyone can access the medicines and healthcare products they need to lead healthy lives.

Learn more

OUR WORK

Innovative finance for development

Our innovative finance tools enable manufacturers and procurers to enter into partnerships that increase access to medical products for people who need them.

Learn more

Latest News & Insight

News – 11 Jan '22

Violet Mordichai joins MedAccess on board apprenticeship programme

MedAccess is pleased to announce the appointment of Violet Mordichai to the position of apprentice to the Board.

News – 02 Dec '21

Q&A: The RTS,S malaria vaccine

Everything you need to know about the decision by Gavi, the Vaccine Alliance to fund the world’s first mass malaria immunisation programmes using the ground-breaking RTS,S/AS01e vaccine.

News – 02 Dec '21

MedAccess welcomes Gavi’s decision to roll out world’s first malaria vaccine

MedAccess has welcomed the decision by Gavi, the Vaccine Alliance to fund the world’s first mass malaria immunisation programmes using the ground-breaking RTS,S/AS01e vaccine.

Insight – 01 Dec '21

HIV viral load testing: “If we could test more often, we would”

HIV viral load testing is the best way for doctors to know if the treatment they prescribe is effective. But access to viral load testing technology is far from equal.